“MUST READ”
tags: weeklylinks
- Big Genomics is converting hype to cash at unsettling speed. After the FDA told consumer genomics company 23andMe it could no longer sell people health data, the company began selling that data to drug and biotech companies. An entire industry, potentially fed by almost anyone who draws blood, spit, or biopsies from you, is emerging to do likewise. Its growth, along with the increasingly routine collection of genetic data by hospitals, will feed the genomics bubble while putting private genetic and health information at increased risk.
tags: weeklylinks
- A lot, if the name is genetically modified organism, or G.M.O., which many people are dead set against. But what if scientists used the precise techniques of today’s molecular biology to give back to plants genes that had long ago been bred out of them? And what if that process were called “rewilding?”
- Genetically Engineered Babies. Germ Line Engineering with CRISPR Leads to Designer Human Embryos | MIT Technology Review
tags: CRISPR
weeklylinks
- Scientists are developing ways to edit the DNA of tomorrow’s children. Should they stop before it’s too late?
tags: dna
weeklylinks
- Amazon.com Inc is in a race against Google Inc to store data on human DNA, seeking both bragging rights in helping scientists make new medical discoveries and market share in a business that may be worth $1 billion a year by 2018.
Academic institutions and
healthcare companies are picking sides between their cloud computing
offerings - Google Genomics or Amazon Web Services - spurring the two to
one-up each other as they win high-profile genomics business, according
to interviews with researchers, industry consultants and analysts.
tags: bioinformatics weeklylinks
tags: weeklylinks
- The introductory chapter has a very good history of Sanger sequencing. It discusses the NGS revolution, although I would not personally describe this as "currently under way" more like a pumpkin coloured tidal wave has washed over the world, and we're all waiting to see what happens next! The main technologies are explained in some detail, and the reviews are pretty much bang up to date. However 454 appears to be alive and kicking in this introduction - perhaps my bias as an Illumina user
tags: weeklylinks
- A new drug that unleashes the body’s immune system to attack tumors can prolong the lives of people with the most common form of lung cancer, doctors reported on Friday, the latest example of the significant results being achieved by this new class of medicines.
In a separate study,
researchers said they had found that a particular genetic signature in the
tumor can help predict which patients could benefit from the immune-boosting
drugs.
tags: weeklylinks
- Merck Millipore, the life sciences business of Merck KGaA, has acquired exclusive worldwide rights allowing it to control and manage the Singulex Life Science Research business, including its Single Molecule Counting (SMC™) technology—including instruments, assays, and services, the companies said today.
- Through the deal, Merck Millipore aims to advance SMC as a leading standard for protein detection by combining its global reach with Singulex’s Erenna® immunoassay platform.
- What Genentech's new Building 35 says about the biotech industry's big Bay Area economic impact - San Francisco Business Times
tags: weeklylinks
- Genentech plans to make more than $2 billion in capital investments through 2016 in California, including lab expansions in South San Francisco and its manufacturing plants in Vacaville and Oceanside. It is building an "employee resource center," including a fitness center, and plans to construct a second child care center to hold another 500 children.
- Any Given Cell: Can Biotech Pioneer Steve Fodor Do it Again? | Xconomy
tags: weeklylinks
- About Us - Complete GenomicsComplete Genomics -
- Complete Genomics is a leader in whole human genome sequencing based in Mountain View, California. Using its proprietary sequencing instruments, chemistry, and software, the company has sequenced more than 20,000 whole human genomes over the past five years. The company’s mission is to improve human health by providing researchers and clinicians with the core technology and commercial systems to understand, prevent, diagnose, and treat diseases and conditions.
- Revolocity - Complete GenomicsComplete Genomics -
tags: weeklylinks
genomics
o
The Revolocity™
system is a complete solution for large-scale, high-quality whole genome
sequencing (WGS) and whole exome sequencing (WES).
- Designed to sequence 10,000 WGS per year and expand to 30,000 WGS per year—surpassing the scalability of any other sequencing solution available today.
tags: weeklylinks
- We have long known that men have a genetic, evolutionary impulse to cheat, because that increases the odds of having more of their offspring in the world.
But now there is intriguing
new research showing that some women, too, are biologically inclined to wander,
although not for clear evolutionary benefits.
tags: weeklylinks
No comments:
Post a Comment